162 results on '"Undre, Nasrullah"'
Search Results
2. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
3. Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients
4. Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device
5. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation
6. Long-Term Prolonged-Release Tacrolimus-Based Immunosuppression in De Novo KidneyTransplant Recipients : 5-Y Prospective Follow-Up of Patients in the ADVANCE study
7. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
8. Co-infections: testing macrolides for added benefit in patients with COVID-19
9. Increase in tacrolimus trough levels after steroid withdrawal
10. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study
11. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial
12. Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization
13. Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus
14. Poster Board #-Session: P100-I PK Modelling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving Once-Daily Tacrolimus (ADVAGRAF).: Abstract# 757
15. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis
16. Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults with Moderate to Severe Atopic Dermatitis
17. A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis
18. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
19. The effect of donor age and recipient characteristics on renal outcomes in patients receiving prolongedrelease tacrolimus after liver transplantation: Post-hoc analyses of the diamond study
20. Pharmacokinetics of tacrolimus-based combination therapies
21. Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients.
22. Quantitation of Tacrolimus inHuman Whole Blood Samples Using the MITRA Microsampling Device.
23. Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients
24. Cover
25. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
26. Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
27. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study
28. Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial
29. Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus to prolonged‐release tacrolimus formulation
30. Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients.
31. Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
32. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
33. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies
34. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy
35. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants
36. Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study.
37. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients
38. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
39. Lower Variability in 24-Hour Exposure During Once-Daily Compared to Twice-Daily Tacrolimus Formulation in Kidney Transplantation
40. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects
41. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation : a substudy of a randomized phase III trial.
42. Tacrolimus pharmacokinetics of once-versus twice-daily formulations in de novo kidney transplantation: A substudy of a randomized phase III trial
43. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
44. Optimizing Micafungin Dosing in Children
45. Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation
46. Pharmacokinetics in Stable Kidney Transplant Recipients After Conversion From Twice-Daily to Once-daily Tacrolimus Formulations
47. Pharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia
48. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study
49. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations
50. Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.